FTO regulates ELK3-mediated metabolic rewiring and represents a unique therapeutic target in T cell leukemia
Science Advances · 30.05.2025 · 11 (22)
DOI: 10.1126/sciadv.adq3052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 30.05.2025. Verfasst von Hao Huang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongnan Hospital of Wuhan University, State Key Laboratory of Metabolism and Regulation in Complex Organisms, Wuhan Univer…. Hauptthemen laut MEDLINE: Alpha-Ketoglutarate-Dependent Dioxygenase FTO, Leukemia, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Understanding the regulation of N6-methyladenosine (m 6 A), the prominent internal modification in mRNA, fosters the development of potential therapeutic strategies for human cancers. While the m 6 A demethylases FTO and ALKBH5 are recognized for their crucial roles in various cancers, their impact on lymphoid leukemia remains uncertain. Using T cell acute lymphoblastic leukemia (T-ALL) as a model system, we identify FTO as a unique vulnerability in T cell leukemia. Knockout of FTO , but not ALKBH5 , significantly suppresses leukemia initiation and progression. Mechanistic analysis reveals that FTO heightens ELK3 mRNA stability in an m 6 A-dependent manner. Elevated ELK3 in turn transcriptionally activates the expression of glycolytic genes. Pharmacological inhibition of FTO suppresses ELK3 expression, hampers glycolysis and manifests remarkable antileukemia efficacy. Our findings unravel the crucial role of FTO in T-ALL and highlight the FTO-ELK3 axis as a key nodule during leukemogenesis, thereby providing a fundamental basis to harness selective FTO antagonist for T-ALL therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Zhongnan Hospital of Wuhan University, State Key Laboratory of Metabolism and Regulation in Complex Organisms, Wuhan University, Wuhan, China.
- Frontier Science Center of Immunology and Metabolism, Medical Research Institute, Wuhan University, Wuhan, China.
- TaiKang Centre for Life and Medical Sciences, Wuhan University, Wuhan, China.
- Department of Physiology, School of Basic Medical Sciences, Wuhan University, Wuhan, China.
- Shanghai Institute of Immunology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Center for Biomedical Big Data, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
ORCID-Profile: Hao Huang, Zhi Chen, Donghai Wang, Hua-Bing Li, Jinyan Huang, Yu Liu, Haojian Zhang, Panagiotis Ntziachristos, Yun Zhao, Guoliang Qing, Hudan Liu
Zitieren
APA
Huang, H., Li, X., Luo, J., Gao, C., Yang, M., Xu, J., Xie, T., Chen, Z., Wang, D., Wang, Y., Li, H. B., Huang, J., Liu, Y., Zhang, H., Ntziachristos, P., Zhao, Y., Qing, G., & Liu, H. (2025). FTO regulates ELK3-mediated metabolic rewiring and represents a unique therapeutic target in T cell leukemia. Science Advances, 11(22). https://doi.org/10.1126/sciadv.adq3052
Vancouver
Huang H, Li X, Luo J, Gao C, Yang M, Xu J, et al. FTO regulates ELK3-mediated metabolic rewiring and represents a unique therapeutic target in T cell leukemia. Science Advances. 2025;11(22). doi:10.1126/sciadv.adq3052
BibTeX
@article{Huang2025,
author = {Huang, Hao and Li, Xinlu and Luo, Jinlian and Gao, Chuan and Yang, Mengjie and Xu, Jin and Xie, Ting and Chen, Zhi and Wang, Donghai and Wang, Yuan and Li, Hua-Bing and Huang, Jinyan and Liu, Yu and Zhang, Haojian and Ntziachristos, Panagiotis and Zhao, Yun and Qing, Guoliang and Liu, Hudan},
title = {FTO regulates ELK3-mediated metabolic rewiring and represents a unique therapeutic target in T cell leukemia},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {22},
doi = {10.1126/sciadv.adq3052}
}
EUVIMED